Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Viridian Therapeutics, Inc.\DE (VRDN)

Viridian Therapeutics reports positive phase 1 data for VRDN-008 in six healthy volunteers

Positive Impact 3 of 5 other

Viridian Therapeutics reported positive phase 1 results for VRDN-008, an extended half-life FcRn inhibitor given subcutaneously, in six healthy volunteers. The company plans to focus its FcRn clinical development on VRDN-008 and to start at least one pivotal trial in 2027, beginning with myasthenia gravis in mid-2027, pending regulatory feedback.

Key points

  • Six healthy volunteers; IgG reduction of 74% at peak and sustained through eight weeks after subcutaneous dosing
  • Extended half-life of 15 to 18 days, five to six times longer than first-generation Fc fragments
  • First pivotal trial planned to start in mid-2027 in myasthenia gravis, pending regulatory feedback
  • Company plans to focus FcRn development on VRDN-008 and may pursue VRDN-006 in the future

The filing

CompanyViridian Therapeutics, Inc.\DE (VRDN)
Form8-K, current report
Filed with the SECNov 9, 2026, 7:33 AM ET
Accession number0001193125-26-452665

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:45 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.